Improving accuracy of RNA-based diagnosis and prognosis of oral cancer by using noninvasive methods.

Improving accuracy of RNA-based diagnosis and prognosis of oral cancer by using noninvasive methods.
复制标题

DOI:
10.1016/j.oraloncology.2017.04.001
复制
发表时间:
2017-06
期刊:
影响因子:
4.8
通讯作者:
Markiewicz MR
Markiewicz MR
中科院分区:
医学2区
文献类型:
--
作者:
Adami GR;Tang JL;Markiewicz MR

文献摘要

被引文献

相似文献

基于RNA的鳞状细胞癌的诊断和预后一直缓慢地进入临床。RNA测量、统计学评价和样品保存的改进,沿着样品数量的增加,还没有使这些方法具有足够的重现性以用于临床。我们认为,在口腔鳞状细胞癌的情况下,变异性的主要来源是样本解剖,这导致了与肿瘤上皮细胞混合的基质的变量。需要非常小心避免的样品的这种异质性使得很难看到肿瘤细胞特异性RNA水平的变化。对数据的评估表明,矛盾的是,口腔病变的刷检样本可能提供比手术采集样本进行miRNA测量更可重复的方法。证据还表明,体液样本可以显示口腔鳞状细胞癌(OSCC)的miRNA变化与肿瘤刷检样本中所见的变化相似,这表明这些样本中的大部分miRNA来自同一来源:肿瘤上皮。我们的结论是,刷检或体液样本可能是上级的手术样本,允许基于miRNA的诊断和预后的口腔鳞癌,因为他们的特点是一个快速的方法,以获得同质的肿瘤细胞和/或RNA。
RNA-based diagnosis and prognosis of squamous cell carcinoma has been slow to come to the clinic. Improvements in RNA measurement, statistical evaluation, and sample preservation, along with increased sample numbers, have not made these methods reproducible enough to be used clinically. We propose that, in the case of squamous cell carcinoma of the oral cavity, a chief source of variability is sample dissection, which leads to variable amounts of stroma mixed in with tumor epithelium. This heterogeneity of the samples, which requires great care to avoid, makes it difficult to see changes in RNA levels specific to tumor cells. An evaluation of the data suggests that, paradoxically, brush biopsy samples of oral lesions may provide a more reproducible method than surgical acquisition of samples for miRNA measurement. The evidence also indicates that body fluid samples can show similar changes in miRNAs with oral squamous cell carcinoma (OSCC) as those seen in tumor brush biopsy samples–suggesting much of the miRNA in these samples is coming from the same source: tumor epithelium. We conclude that brush biopsy or body fluid samples may be superior to surgical samples in allowing miRNA-based diagnosis and prognosis of OSCC in that they feature a rapid method to obtain homogeneous tumor cells and/or RNA.